Clinical trial
A Phase 3, Multi-center, Placebo-controlled, Randomized, Double-blind 26-week Study to Assess the Safety and Efficacy of CaPre® in Patients With Severe Hypertriglyceridemia.
NCT03398005 is registered in ClinicalTrials.gov with Grace Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multi-center, Placebo-controlled, Randomized, Double-blind 26-week Study to Assess the Safety and Efficacy of CaPre® in Patients With Severe Hypertriglyceridemia.
- Lead sponsor
- Grace Therapeutics Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 23, 2018
- Completion date
- November 20, 2019
- Enrollment
- 256 (actual)
- Sites
- 69
Conditions
As the registry lists them; a condition with its own page is linked.